Now that the National Cholesterol Education Program has updated its clinical practice guidelines on cholesterol management, one of the questions is how health care providers can reach the lower treatment goals for low-density lipoprotein (LDL) cholesterol for patients at high and moderately high risk of a heart attack.
Read More
Some physicians advocate early, aggressive therapy to help reduce low-density lipoprotein (LDL) cholesterol levels. One new study, however, indicates that patients treated with high-dose simvastatin (Zocor) did not show a significant reduction in the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, readmission for acute coronary syndrome (ACS), and stroke.
Read More
Rosuvastatin calcium (Crestor) just passed its one-year anniversary since being approved by the U.S. Food and Drug Administration (FDA). Although by reports it has generated almost $4 billion in annual sales for AstraZeneca, the approval initially brought mixed feelings for many physicians, says Peter H. Jones, MD.
Read More
Many elderly Americans still are being prescribed potentially inappropriate medications, according to a study published in the Aug. 9/23 issue of the Archives of Internal Medicine.
Read More
Patients warned of clinical differences in thyroid meds; Higher costs affect MS patientsÂ’ adherence to medications; FDA issues warnings, label changes; Survey highlights importance of pharmacist/patient relationship.
Read More
Pentetate calcium trisodium injection (Ca-DTPA) and pentetate zinc trisodium injection (Zn-DTPA) by Hameln Pharmaceuticals, GmbH, of Hameln, Germany.
Read More
Apomorphine was recognized in 1960 to affect dopamine receptors in the treatment of ParkinsonÂ’s disease (PD). The U.S. Food and Drug Administration (FDA) designated apomorphine as an orphan drug in 1991 for the treatment of hypomobility in idiopathic stage intravenous (IV) PD patients.
Read More
